

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>Date Submitted: November 11, 2008 (use as many sheets as necessary)</p>				<p><b>Complete if Known</b></p> <table border="1"> <tr> <td><b>Application Number</b></td> <td>10/566,358</td> </tr> <tr> <td><b>Filing Date</b></td> <td>7/30/2004</td> </tr> <tr> <td><b>First Named Inventor</b></td> <td>Dominique BOUREL</td> </tr> <tr> <td><b>Art Unit</b></td> <td>1644</td> </tr> <tr> <td><b>Examiner Name</b></td> <td>Chun CROWDER</td> </tr> <tr> <td><b>Attorney Docket Number</b></td> <td>065691-0433</td> </tr> </table>		<b>Application Number</b>	10/566,358	<b>Filing Date</b>	7/30/2004	<b>First Named Inventor</b>	Dominique BOUREL	<b>Art Unit</b>	1644	<b>Examiner Name</b>	Chun CROWDER	<b>Attorney Docket Number</b>	065691-0433
<b>Application Number</b>	10/566,358																
<b>Filing Date</b>	7/30/2004																
<b>First Named Inventor</b>	Dominique BOUREL																
<b>Art Unit</b>	1644																
<b>Examiner Name</b>	Chun CROWDER																
<b>Attorney Docket Number</b>	065691-0433																
Sheet	1	of	2														

## U.S. PATENT DOCUMENTS

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> /Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			
	A1	WO 01/77181 A1	10/18/2001	ARNAUD GLACET et al.	
	A2	EP 0 576 093 A1	12/29/1993	ASSOCIATION POUR L'ESSOR DE LA TRANSFUSION SANGUINE DANS LA REGION DU	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A3	B M KUMPEL et al., "Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fc $\gamma$ RIIIa (CD16)", Clinical & Experimental Immunology, vol. 132, no. 1, April 2003, pp. 81-86.	
	A4	T. SHINKAWA et al., "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", Journal of Biological Chemistry, vol. 278, no. 5, January 31, 2003, pp. 3466-3473.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/566,358
Date Submitted: November 11, 2008 (use as many sheets as necessary)				Filing Date	7/30/2004
				First Named Inventor	Dominique BOUREL
				Art Unit	1644
				Examiner Name	Chun CROWDER
Sheet	2	of	2	Attorney Docket Number	065691-0433

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A5	P. UMANA et al., "ENGINEERED GLYCOFORMS OF AN ANTINEUROBLASTOMA IgG1 WITH OPTIMIZED ANTIBODY-DEPENDENT CELLULAR CYTOTOXIC ACTIVITY", NATURE BIOTECHNOLOGY, vol. 17, February 1999, pp. 176-180.			
	A6	R L SHIELDS et al., "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity", Journal of Biological Chemistry, vol. 277, no. 30, July 26, 2002, pp. 26733-26740.			
	A7	Guillaume CARTRON et al., "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa gene", BLOOD, vol. 98, no. 11, Part 1, November 16, 2001, page 602a.			
	A8	J.S. CROWE et al., "HUMANIZED MONOClonAL ANTIBODY CAMPATH-1H MYELOMA CELL EXPRESSION OF GENOMIC CONSTRUCTS NUCLEOTIDE SEQUENCE OF cDNA CONSTRUCTS AND COMPARISON OF EFFECTOR MECHANISMS OF MYELOMA AND CHINESE HAMSTER OVARY CELL DERIVED MATERIAL", Clinical and Experimental Immunology, vol. 87, no. 1, 1992, pp. 105-110.			
	A9	M.R. LIFELY et al., "Glycosylation and biological-activity of CAMPATH-1H expressed in different cell-lines and grown under different culture conditions", GLYCOBIOLOGY, vol. 5, no. 8, December 1995, pp. 813-822.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.